Full-Time

Software Engineer Intern New Grad

Color

Color

501-1,000 employees

Genetic testing and health screening platform

Compensation Overview

$125k - $140k/yr

South San Francisco, CA, USA

In Person

Bachelor's

Category
Software Engineering (1)
Required Skills
LLM
Python
React.js
SQL
Machine Learning
AWS
Observability
REST APIs
Web Development
HTML/CSS
Django

Get referred to Color

See people who can refer or advise you

Requirements
  • The candidate must have graduated in 2025 or 2026 with a four-year degree in Computer Science.
  • The candidate must have experience using artificial intelligence tools, such as code generation tools or Copilot, in development workflows.
  • The candidate must be familiar with web development and modern web stacks including Python, Django, Amazon Web Services, Structured Query Language, Representational State Transfer application programming interfaces, React, HTML5, CSS3, and ECMAScript 6 or later.
  • The candidate must be committed to producing high-quality code and eliminating unnecessary duplication and awkward workarounds.
  • The candidate must be motivated to work with rigorous engineering practices including code reviews, automated testing, logging, monitoring, and alerting.
Responsibilities
  • Contribute to embedding artificial intelligence-driven automation into care workflows to increase care team capacity without sacrificing quality.
  • Extend and build patient experiences across onboarding and enrollment, testing and resulting, treatment experiences, and survivorship.
  • Build developer infrastructure to expand developer efficiencies and enable new artificial intelligence tooling.
  • Learn Color’s systems through cohort onboarding and support from senior engineers and leads.
  • Develop skills in engineering design, code review, testing, observability, and collaboration with product and engineering peers.
Desired Qualifications
  • Experience building or integrating large language model-powered features.

Color provides genetic testing and health screening services for individuals, healthcare providers, and employers. Its products include genetic tests and health screenings (including COVID-19 testing) that customers can buy directly or through providers, with options for employer health programs. The tests work by collecting a sample from the user, analyzing genetic data and health markers, and delivering results through Color’s platform, along with access to genetic counseling to help interpret findings. The company differentiates itself through its broad accessibility (direct-to-consumer, provider and employer partnerships), emphasis on privacy and data security, and a combination of preventive health insights with counseling. Color’s goal is to make genetic testing and preventive health screenings affordable and accessible to improve individual and workplace health and productivity.

Company Size

501-1,000

Company Stage

Series E

Total Funding

$482M

Headquarters

Burlingame, California

Founded

2014

Get referred to Color

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Evry Health rolled out Color to members on January 7, 2026.
  • Color launched FDA-cleared at-home HPV screening on June 25, 2026.
  • More than 1 million people gain Color access through employers or health plans in 2026.

What critics are saying

  • Color’s workforce fell from 726 to 607 by March 2026, signaling contraction.
  • Color still depends on employer and health-plan budgets; procurement slumps delay revenue expansion.
  • A failed outcomes proof in 2026 would kill Color’s premium-cancer-care thesis and stall sales.

What makes Color unique

  • Color runs the only nationwide, ASCO-certified virtual cancer clinic, launched May 2026.
  • Color Medical’s 50-state oncologist-led group closes screening, diagnosis, and survivorship loops.
  • Color pairs in-house CLIA lab workflows with Google Cloud AI and at-home HPV testing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive salary

Comprehensive medical, dental, vision, life, and disability benefits. Including employer HSA contributions.

401(k) match

Monthly lunch, phone, and wifi stipend for remote employees

Generous vacation policy, paid holidays and company-wide recharge days

Monthly stipend to spend on your well being

Equal paid parental leave for birthing and non-birthing parents

Four complementary clinical-grade genetic testing kits for you and your family

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
PR Newswire
Jun 30th, 2026
Color's virtual cancer clinic expands expert medical opinions, saves patients average of $62K through multidisciplinary reviews

Color, a virtual cancer clinic, has expanded its Expert Medical Opinion services with a new peer-to-peer programme connecting patients and treating oncologists with specialists from NCI-Designated Cancer Centers. The service provides multidisciplinary reviews at every clinical decision point through Color's ASCO-certified virtual clinic. Across all patients using the service, 95% have had at least one recommended change in their care, generating an estimated $62,000 in average cost savings per patient. Multidisciplinary case reviews have been shown to improve survival rates by over 30%. Color's expanded expert network now includes specialists in breast cancer, haematologic malignancies, palliative medicine, and various other oncology subspecialties from institutions including Stanford Cancer Institute, Mass General Hospital, and UC San Francisco. The peer-to-peer programme proactively identifies cases through claims and prior authorisation data.

Color
Jun 25th, 2026
Closing the cervical cancer screening gap with FDA-cleared at-home HPV testing.

Closing the cervical cancer screening gap with FDA-cleared at-home HPV testing. Dany Matar COO, Color Mawadda Alnaeeli Sr. Director, Clinical Testing Operations, Color This week, Color announced a new addition to its cancer screening and early detection program: the FDA-cleared HPV self-collection kit from BD Waters to test for cervical cancer risk. Why this test, and why cervical cancer? The test can be done at home in under a minute, doesn't require a pelvic exam, and is just as accurate as clinical collection options. It also aligns with American Cancer Society and other screening body guidelines. And cervical cancer happens to be one of the most preventable cancers Color know of. HPV is a common sexually transmitted infection responsible for over 90% of cervical cancer cases. Color has effective vaccines, reliable screening tests and clear clinical guidelines to intervene before a cancer shows up. Yet one in four eligible women are not up to date with cervical cancer screening, and 60% of cervical cancers occur in people who haven't been screened in the last five years, or ever. Color's approach. Early cancer detection is a core pillar of Color's Virtual Cancer Clinic, which spans the entire cancer care spectrum from screening and active treatment, all the way through survivorship care. Early stage cancer means up to 99% chances of survival, and 3-5x lower cost of care. In many cases, it can also mean intervening in a pre-cancer stage, long before any cancer is diagnosed in a patient. The new cervical cancer test joins Color's broader suite of at-home screening and early detection services that make access to early cancer detection easy and convenient for patients. Through its ASCO-Certified Virtual Cancer Clinic, Color Early Detection program provides: * At-home tests for the most common guideline-recommended cancer screenings, processed at Color's in-house CAP-accredited, CLIA-certified lab * A high-quality, lower-cost nationwide imaging screening network * Cancer risk identification and clinical management * Genetic risk testing for hereditary cancer risk * High touch clinical management of patients with abnormal results All of it delivered through Color Medical's oncologist-led, 50-state medical group, with clinical accountability built in at every step. For individuals who face barriers to traditional pelvic exams due to discomfort, scheduling, or transportation, this new, private, at-home collection option meaningfully expands access for those who need to get screened. Why this matters for Health Plan and employer populations. Cervical cancer is not a unique phenomenon when it comes to a lack of screening adherence and follow up. An estimated 69% of U.S. adults are behind on at least one routine cancer screening, according to the Prevent Cancer Foundation, and a national survey by the American Cancer Society (ACS CAN) found that 31% of adults are more than a full year overdue for their guideline-recommended screenings. For employers and health plans, these gaps represent both a human cost and a financial one. Undetected cancer means later-stage diagnoses, more complex treatment, worse outcomes, and significantly higher costs of care. Closing that gap requires more than just making a test available. It requires a program that removes the behavioral, psychological and logistical barriers that prevent people from getting their screenings done. Color allows employers and health plans to offer members a more effective approach to cancer screening and early detection, and an approach that will deliver results within the first 3-6 months from implementing the program. That means: * Clinical ordering and follow-up on every test. Color Medical's oncologist-led clinical team orders every screening test based on the patient's risk and recommended guidelines, and follows up on every result. There's no gap between "test administered" and "result acted on." * 100% clinical follow-up on every abnormal result. This isn't aspirational. Color has demonstrated 100% clinical follow-up for every abnormal screening result across its program. When something is flagged, a clinician follows up. Every time. No patient is left behind. * Faster time to diagnosis. For patients with abnormal results, Color has reduced the time it takes to get to a cancer diagnosis by 66% compared to traditional network models. Earlier diagnosis means more treatment options, faster interventions, better outcomes, and lower costs. Color track this and hold ourselves accountable to it. * Proven screening gap closure. Color's program has demonstrated a 77% increase in screening adherence across its populations. Color populations are getting screened, and staying up to date on their screenings. * Reduced costs of care delivery. Color's integrated model reduces costs of care delivery relative to traditional network approaches. Investing in rigorous screening processes pays off. Color guarantee that the program will save more than it will cost from the first year it launches. The at-home HPV kit fits directly into this model. It's not a standalone product, nor a part of a collection of disconnected point solutions. It's one component of a coordinated clinical program in which Color's team manages the full arc of the patient's care from cancer risk assessment, to test ordering and processing in its in-house lab, through clinical follow-up and cancer diagnosis. Color is excited about making this testing modality available for its patients and customers as Color continue to expand the impact of its Virtual Cancer Clinic. Finally, great cancer care is as critical as catching cancer early. Color'll also be sharing soon additional improvements Color is launching for its Active Cancer Treatment services, another key pillar of its Virtual Cancer Clinic. Stay tuned!

Color
Mar 31st, 2026
Dr. Karen knudsen joins Color as Strategic Advisor.

Dr. Karen knudsen joins Color as Strategic Advisor. Published March 31, 2026 Color is honored to welcome Karen E. Knudsen, MBA, PhD, as a Strategic Advisor to Color Health. Dr. Karen knudsen joins Color Health as strategic advisor. Dr. Knudsen is the Chief Executive Officer of the Parker Institute for Cancer Immunotherapy (PICI) and a globally recognized cancer scientist and healthcare leader. Throughout her career, she has helped shape the future of cancer research, care delivery, and collaboration across the oncology ecosystem. In her prior role as the CEO of the American Cancer Society, Dr. Knudsen helped shape Color's Virtual Cancer Clinic (VCC). Today, the Color VCC is the only nationwide, oncologist-led cancer care platform, bringing high-quality, comprehensive cancer care to patients regardless of where they live. At PICI, Dr. Knudsen is leading efforts to advance bold science and accelerate breakthrough immunotherapies through cross-institutional collaboration. With more than 100 active studies spanning clinical trials, preclinical discoveries, and emerging technologies, the institute is helping bring innovative immune-based treatments to patients faster. At Color, Dr. Knudsen will help guide the continued evolution and expansion of the VCC and support its mission to deliver accessible, high-impact cancer care at scale for employer, union, health plan and public sector populations. As Dr. Knudsen shares: "Transforming cancer outcomes requires both scientific innovation and new models for delivering care. Color's innovation on the care delivery front has been truly game changing since the launch of its Virtual Cancer Clinic, with plenty of room to grow. The Color VCC detects cancer earlier through guidelines-based screening, while improving outcomes and costs at every stage. Utilizing risk-based assessments, at-home screening and in-networking imaging through its integrated clinical platform, Color's model has already produced impressive results. The VCC has been shown to increase screening adherence by 77%, and cut time to diagnosis by 66%, getting patients into the right treatment in days, not months. I'm excited to once again work with Color to continue innovating on best-in-class cancer care delivery to those in need, at every stage." Color is incredibly fortunate to partner with Dr. Knudsen as Color continue building the future of cancer care. Welcome to Color, Karen!

Healthcare IT Today
Feb 23rd, 2026
Lotus raises $41M to replace primary care with AI-powered physician model

Lotus Health AI has raised $35 million in a Series A round co-led by Kleiner Perkins and CRV, bringing total funding to $41 million. CRV general partner Saar Gur, who led early investments in DoorDash and Ring, will join the board. The San Francisco-based startup combines medical AI, unified patient data and board-certified physicians to deliver primary care at scale. The platform syncs medical records, labs and wearable data, supporting over 50 languages with 24/7 availability. Physicians review AI-generated guidance and prescribe medications when needed. Lotus generates revenue through premium sponsorships rather than patient billing, aiming to make care accessible without insurance. Investors include Joe Montana's Liquid 2, healthcare founders from Clover Health and Color Genomics, and physicians from Harvard and Stanford.

PR Newswire
Feb 12th, 2026
Maven and Color Health partner to integrate oncofertility care with cancer treatment

Maven Clinic and Color Health have partnered to integrate fertility preservation into cancer care, creating an oncofertility programme initially available through employers and health plans. The collaboration combines Color's oncologist-led cancer care with Maven's women's health platform to help cancer patients understand and preserve fertility options. Cancer rates among young adults are rising, with roughly 70,000 diagnosed annually, yet only 50% of patients discuss fertility preservation with their oncologist. Cancer treatments can permanently impact fertility, making early intervention critical. Through the partnership, Color patients of childbearing age will access Maven's oncofertility care pathway, including virtual teams of oncologists, fertility specialists and mental health providers. Services cover egg, sperm and embryo freezing, plus expedited access to Maven's network of fertility clinics. The programme aims to make fertility preservation a standard part of cancer care rather than an afterthought.